HomeSGX-LISTED COMPANIESThakral Corporation's Record 1H25 Profit and GemLife IPO Success

Thakral Corporation’s Record 1H25 Profit and GemLife IPO Success

Published on

spot_img

Thakral Corporation Ltd achieved a remarkable profit, significantly boosted by the successful public listing of GemLife Communities Group on the ASX. The company’s lifestyle division demonstrated robust performance, driven by strong demand for beauty products in China and expanding drone adoption in South Asia. Strategic initiatives include new Nespresso retail ventures and real estate developments in India, positioning the Group for sustained growth across diverse markets.

• Discover how a major associate’s successful public listing transformed the investment landscape and redefined its classification

• Explore the booming demand for lifestyle products, from beauty essentials to cutting-edge drone technology, across key Asian markets

• Uncover strategic moves in India’s growing economy, including pioneering new retail ventures, ambitious real estate developments, and expanding drone-related manufacturing

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...